Gilead Sciences, Inc. logo
Gilead Sciences, Inc. (GILD)
Compare

Gilead Sciences, Inc. (GILD) EV/Assets Ratio: 2.97x

popular:market cap|pe ratio|revenue|price history|total return

Is Gilead Sciences, Inc.’s EV/Assets ratio high or low?

Gilead Sciences, Inc.'s EV/Assets ratio of 2.97x is 38% above its 5-year average of 2.15x, near the high end of its 5-year range (1.39x–3.64x).

The EV/Assets ratio for Gilead Sciences, Inc. (GILD) is 2.97x as of Wednesday, June 10, 2026. It is below its 12-month average by 2.73% (3.05x).

Enterprise Value|EV/Sales|Total Assets|All Metrics

GILD EV/Assets Ratio Chart

GILD EV/Assets Ratio
2.97x+7.61% 1Y
Zoom

GILD Average EV/Assets Ratio Chart

GILD Current vs Average EV/Assets Ratio Chart

GILD EV/Assets Ratio Metrics

EV/ASSETS RATIO

2.97x

EV/ASSETS RATIO AVG TTM

3.05x

EV/ASSETS RATIO AVG 3Y

2.44x

EV/ASSETS RATIO AVG 5Y

2.15x

EV/ASSETS RATIO AVG 10Y

1.98x

EV/ASSETS RATIO AVG 15Y

2.66x

EV/ASSETS RATIO AVG 20Y

3.49x

CURRENT VS TTM AVG

-2.73%

CURRENT VS 3Y AVG

+21.91%

CURRENT VS 5Y AVG

+38.10%

CURRENT VS 10Y AVG

+50.36%

CURRENT VS 15Y AVG

+11.64%

CURRENT VS 20Y AVG

-14.98%

GILD Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Gilead Sciences, Inc. (GILD)—2.97x3.05x2.44x2.15x
Abbott Laboratories (ABT)$154.66B1.65x2.50x2.67x2.75x
Intuitive Surgical, Inc. (ISRG)$146.44B7.30x8.88x9.09x8.50x
Pfizer Inc. (PFE)$146.36B1.01x1.00x1.03x1.28x
Danaher Corporation (DHR)$130.25B1.72x1.98x2.16x2.26x
CVS Health Corporation (CVS)$125.16B0.77x0.67x0.63x0.70x
Thermo Fisher Scientific Inc. (TMO)$179.45B1.94x2.16x2.33x2.57x
Amgen Inc. (AMGN)$183.75B2.49x2.46x2.27x2.38x
Bristol-Myers Squibb Company (BMY)$114.14B1.72x1.55x1.56x1.64x
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B4.10x4.45x4.69x4.46x

Gilead Sciences, Inc. EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Gilead Sciences, Inc. EV/Assets Ratio FAQ

What is the EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The EV/Assets ratio for GILD stock is 2.97x.
Is Gilead Sciences, Inc.'s EV/Assets ratio high or low?
Gilead Sciences, Inc.'s EV/Assets ratio of 2.97x is 38% above its 5-year average of 2.15x, near the high end of its 5-year range (1.39x–3.64x).
What is the TTM average EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The TTM average EV/Assets ratio for GILD stock is 3.05x.
What is the 3Y average EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The 3Y average EV/Assets ratio for GILD stock is 2.44x.
What is the 5Y average EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The 5Y average EV/Assets ratio for GILD stock is 2.15x.
What is the 10Y average EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The 10Y average EV/Assets ratio for GILD stock is 1.98x.
What is the 15Y average EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The 15Y average EV/Assets ratio for GILD stock is 2.66x.
What is the 20Y average EV/Assets ratio for Gilead Sciences, Inc. (GILD)?
The 20Y average EV/Assets ratio for GILD stock is 3.49x.

Gilead Sciences, Inc. EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-102.97x
2026-06-093.05x
2026-06-083.11x
2026-06-053.14x
2026-06-043.14x
2026-06-033.13x
2026-06-023.10x
2026-06-013.18x
2026-05-293.25x
2026-05-283.29x
2026-05-273.24x
2026-05-263.24x
2026-05-223.25x
2026-05-213.17x
2026-05-203.17x
2026-05-193.17x
2026-05-183.15x
2026-05-153.15x
2026-05-143.20x
2026-05-133.22x
2026-05-123.27x
2026-05-113.23x
2026-05-083.18x
2026-05-073.25x
2026-05-063.18x
2026-05-053.12x
2026-05-043.11x
2026-05-013.08x
2026-04-303.07x
2026-04-293.02x
2026-04-283.03x
2026-04-273.00x
2026-04-243.06x
2026-04-233.13x
2026-04-223.11x
2026-04-213.12x
2026-04-203.17x
2026-04-173.21x
2026-04-163.23x
2026-04-153.26x
2026-04-143.27x
2026-04-133.24x
2026-04-103.24x
2026-04-093.30x
2026-04-083.29x
2026-04-073.24x
2026-04-063.26x
2026-04-023.25x
2026-04-013.27x
2026-03-313.25x
2026-03-303.18x
2026-03-273.14x
2026-03-263.19x
2026-03-253.22x
2026-03-243.22x
2026-03-233.20x
2026-03-203.20x
2026-03-193.28x
2026-03-183.29x
2026-03-173.35x
2026-03-163.37x
2026-03-133.37x
2026-03-123.37x
2026-03-113.39x
2026-03-103.44x
2026-03-093.40x
2026-03-063.34x
2026-03-053.37x
2026-03-043.44x
2026-03-033.43x
2026-03-023.47x
2026-02-273.45x
2026-02-263.34x
2026-02-253.41x
2026-02-243.42x
2026-02-233.51x
2026-02-203.54x
2026-02-193.54x
2026-02-183.57x
2026-02-173.63x
2026-02-133.62x
2026-02-123.55x
2026-02-113.64x
2026-02-103.46x
2026-02-093.55x
2026-02-063.57x
2026-02-053.50x
2026-02-043.43x
2026-02-033.37x
2026-02-023.36x
2026-01-303.34x
2026-01-293.29x
2026-01-283.29x
2026-01-273.32x
2026-01-263.25x
2026-01-233.21x
2026-01-223.11x
2026-01-213.07x
2026-01-202.96x
2026-01-162.98x
2026-01-152.90x
2026-01-142.96x
2026-01-132.91x
2026-01-122.93x
2026-01-092.90x
2026-01-082.89x
2026-01-072.96x
2026-01-062.90x
2026-01-052.84x
2026-01-022.91x
2025-12-312.93x
2025-12-302.94x
2025-12-292.98x
2025-12-262.97x
2025-12-242.99x
2025-12-232.98x
2025-12-222.96x
2025-12-192.96x
2025-12-182.90x
2025-12-172.90x
2025-12-162.85x
2025-12-152.87x
2025-12-122.88x
2025-12-112.94x
2025-12-102.90x
2025-12-092.86x
2025-12-082.90x
2025-12-052.90x
2025-12-042.93x
2025-12-032.98x
2025-12-022.96x
2025-12-012.96x
2025-11-283.00x
2025-11-263.03x
2025-11-253.02x
2025-11-242.98x
2025-11-213.01x
2025-11-202.98x
2025-11-193.04x
2025-11-183.03x
2025-11-172.96x
2025-11-142.98x
2025-11-132.98x
2025-11-122.94x
2025-11-112.93x
2025-11-102.83x
2025-11-072.85x
2025-11-063.13x
2025-11-053.12x
2025-11-043.13x
2025-11-033.10x
2025-10-313.05x
2025-10-303.02x
2025-10-293.02x
2025-10-283.01x
2025-10-273.07x
2025-10-243.08x
2025-10-233.07x
2025-10-223.09x
2025-10-213.15x
2025-10-203.13x
2025-10-173.12x
2025-10-163.01x
2025-10-153.02x
2025-10-143.02x
2025-10-133.02x
2025-10-102.99x
2025-10-092.98x
2025-10-083.02x
2025-10-072.99x
2025-10-062.91x
2025-10-032.89x
2025-10-022.85x
2025-10-012.86x
2025-09-302.86x
2025-09-292.89x
2025-09-262.88x
2025-09-252.86x
2025-09-242.92x
2025-09-232.93x
2025-09-222.89x
2025-09-192.93x
2025-09-182.91x
2025-09-172.88x
2025-09-162.85x
2025-09-152.89x
2025-09-122.94x
2025-09-113.01x
2025-09-102.95x
2025-09-092.96x
2025-09-082.97x
2025-09-052.95x
2025-09-042.90x
2025-09-032.90x
2025-09-022.89x
2025-08-292.90x
2025-08-282.89x
2025-08-272.92x
2025-08-262.94x
2025-08-252.93x
2025-08-222.94x
2025-08-212.97x
2025-08-203.03x
2025-08-193.01x
2025-08-183.01x
2025-08-153.02x
2025-08-143.04x
2025-08-133.06x
2025-08-123.06x
2025-08-113.07x
2025-08-083.04x
2025-08-072.84x
2025-08-062.76x
2025-08-052.81x
2025-08-042.86x
2025-08-012.83x
2025-07-312.81x
2025-07-302.86x
2025-07-292.85x
2025-07-282.82x
2025-07-252.89x
2025-07-242.83x
2025-07-232.84x
2025-07-222.76x
2025-07-212.72x
2025-07-182.72x
2025-07-172.73x
2025-07-162.75x
2025-07-152.73x
2025-07-142.80x
2025-07-112.75x
2025-07-102.86x
2025-07-092.83x
2025-07-082.78x
2025-07-072.80x
2025-07-032.79x
2025-07-022.79x
2025-07-012.79x
2025-06-302.78x
2025-06-272.77x
2025-06-262.70x
2025-06-252.66x
2025-06-242.69x
2025-06-232.67x
2025-06-202.72x
2025-06-182.71x
2025-06-172.71x
2025-06-162.77x
2025-06-132.76x
2025-06-122.80x
2025-06-112.74x
2025-06-102.76x
2025-06-092.82x
2025-06-062.81x
2025-06-052.77x
2025-06-042.73x
2025-06-032.74x
2025-06-022.73x
2025-05-302.76x
2025-05-292.78x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

Related Metrics

Enterprise ValueEV/SalesTotal AssetsAll Metrics

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA
17,600 employees
www.gilead.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
View full financials